{"DataElement":{"publicId":"4973766","version":"1","preferredName":"Leukemia Primary Morphology Classification Type","preferredDefinition":"The type of first form and structure of a malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood.","longName":"LeukPrimMorpTp","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"4973733","version":"1","preferredName":"Leukemia Primary Morphology Classification","preferredDefinition":"Information related to the classification of first form and structure of a malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood.","longName":"2177113v1.0:4973731v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"2177113","version":"1","preferredName":"Leukemia","preferredDefinition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood.  Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present.  Leukemia is usually associated with anemia, fever, hemorrhagic episodes and splenomegaly.  Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia.  Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years. -- 2004","longName":"Leukemia","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Leukemia","conceptCode":"C3161","definition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACAAECCE-7A87-657B-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"4973731","version":"1","preferredName":"Primary Morphology Classification","preferredDefinition":"Occurring first in time or sequence; original; of greatest rank or importance or value.:The science of the form and structure of organisms (plants, animals, and other forms of life), or of their parts, and the study or science of the same.  In pathology, the specific appearance of cells and tissues (normal and abnormal) under the light or electron microscope.:A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","longName":"C25251:C17943:C25161","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary","conceptCode":"C25251","definition":"Occurring first in time or sequence; original; of greatest rank or importance or value.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Morphology","conceptCode":"C17943","definition":"The science of the form and structure of organisms (plants, animals, and other forms of life), or of their parts, and the study or science of the same.  In pathology, the specific appearance of cells and tissues (normal and abnormal) under the light or electron microscope.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Classification","conceptCode":"C25161","definition":"A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D88FEC4-0D4B-54AB-E050-BB89AD4366F5","latestVersionIndicator":"Yes","beginDate":"2015-08-17","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-17","modifiedBy":"ONEDATA","dateModified":"2015-08-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D88FEC4-0D5C-54AB-E050-BB89AD4366F5","latestVersionIndicator":"Yes","beginDate":"2015-08-17","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-17","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"4973752","version":"1","preferredName":"Leukemia Primary Morphology Type","preferredDefinition":"The type of first form and structure of a malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood.","longName":"4973752v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"CML-BC","valueDescription":"Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","ValueMeaning":{"publicId":"4360175","version":"1","preferredName":"Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","longName":"4360175","preferredDefinition":"An advanced phase of chronic myelogenous leukemia.  It is characterized by: 1.  the presence of blasts in the peripheral blood or bone marrow that are at least 20% of the peripheral blood white cells or of the nucleated cells in the bone marrow respectively, or 2. an extramedullary proliferation of blasts, and/or 3. when there are large aggregates and clusters of blasts in the bone marrow biopsy specimen (adapted from WHO, 2001).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C9110","definition":"An advanced phase of chronic myeloid leukemia.  It is characterized by: 1.  the presence of blasts in the peripheral blood or bone marrow that are at least 20% of the peripheral blood white cells or of the nucleated cells in the bone marrow respectively, or 2. an extramedullary proliferation of blasts, and/or 3. when there are large aggregates and clusters of blasts in the bone marrow biopsy specimen (adapted from WHO, 2001).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC2FF07C-5BDE-E43C-E040-BB89AD4336C7","latestVersionIndicator":"Yes","beginDate":"2014-06-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-06-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1D88FEC4-0EB4-54AB-E050-BB89AD4366F5","beginDate":"2015-08-17","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-17","modifiedBy":"ONEDATA","dateModified":"2015-08-17","deletedIndicator":"No"},{"value":"CML-AP","valueDescription":"Chronic Myelogenous Leukemia, BCR-ABL1 Positive Accelerated Phase of Disease","ValueMeaning":{"publicId":"4973753","version":"1","preferredName":"Chronic Myelogenous Leukemia, BCR-ABL1 Positive Accelerated Phase of Disease","longName":"4973753","preferredDefinition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival.: The phase of a disease characterized by laboratory and clinical findings that indicate rapid progression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C3174","definition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Accelerated Phase of Disease","conceptCode":"C36155","definition":"The phase of a disease characterized by laboratory and clinical findings that indicate rapid progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D88FEC4-0EC2-54AB-E050-BB89AD4366F5","latestVersionIndicator":"Yes","beginDate":"2015-08-17","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1D88FEC4-0EDD-54AB-E050-BB89AD4366F5","beginDate":"2015-08-17","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-17","modifiedBy":"ONEDATA","dateModified":"2015-08-17","deletedIndicator":"No"},{"value":"CML-CP","valueDescription":"Chronic Myelogenous Leukemia, BCR-ABL1 Positive Chronic Phase","ValueMeaning":{"publicId":"4973754","version":"1","preferredName":"Chronic Myelogenous Leukemia, BCR-ABL1 Positive Chronic Phase","longName":"4973754","preferredDefinition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival.: Refers to the early stages of chronic myelogenous leukemia or chronic lymphocytic leukemia. The number of mature and immature abnormal white blood cells in the bone marrow and blood is higher than normal, but lower than in the accelerated or blast phase.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C3174","definition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Chronic Phase","conceptCode":"C28262","definition":"Refers to the early stages of chronic myelogenous leukemia or chronic lymphocytic leukemia. The number of mature and immature abnormal white blood cells in the bone marrow and blood is higher than normal, but lower than in the accelerated or blast phase.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D88FEC4-0EEA-54AB-E050-BB89AD4366F5","latestVersionIndicator":"Yes","beginDate":"2015-08-17","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1D88FEC4-0F05-54AB-E050-BB89AD4366F5","beginDate":"2015-08-17","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-17","modifiedBy":"ONEDATA","dateModified":"2015-08-17","deletedIndicator":"No"},{"value":"MDS not further subclassified","valueDescription":"MDS not further subclassified","ValueMeaning":{"publicId":"4860794","version":"1","preferredName":"MDS not further subclassified","longName":"4860794","preferredDefinition":"MDS not further subclassified","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"18199818-F6AA-18F2-E050-BB89AD4304B5","latestVersionIndicator":"Yes","beginDate":"2015-06-09","endDate":null,"createdBy":"LEEW","dateCreated":"2015-06-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1D88FEC4-0F0F-54AB-E050-BB89AD4366F5","beginDate":"2015-08-17","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-17","modifiedBy":"ONEDATA","dateModified":"2015-08-17","deletedIndicator":"No"},{"value":"MDS RAEB-T","valueDescription":"Myelodysplastic Syndrome Refractory Anemia with Excess Blasts in Transformation","ValueMeaning":{"publicId":"4973755","version":"1","preferredName":"Myelodysplastic Syndrome Refractory Anemia with Excess Blasts in Transformation","longName":"4973755","preferredDefinition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001): Refractory anemia with excess blasts in transformation (RAEB-T) is characterised by dysplastic features of the myeloid and usually erythroid progenitor cells in the bone marrow and an increased number of myeloblasts in the peripheral blood.  The peripheral blood blast count ranges from 20% to 30%.  RAEB-T used to be a subcategory of myelodysplastic syndromes in the past.  Recently, the term has been eliminated from the WHO based classification of myelodysplastic syndromes.  The reason is that the percentage of peripheral blood blasts required for the diagnosis of acute myeloid leukemia has been reduced to 20%.  The elimination of the RAEB-T term by the WHO experts has created confusion and ongoing arguments.  Currently, according to WHO classification, the vast majority of RAEB-T cases are best classified as acute leukemias (acute leukemias with multilineage dysplasia following myelodysplastic syndrome).  A minority of cases are part of RAEB-2.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome","conceptCode":"C3247","definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Refractory Anemia with Excess Blasts in Transformation","conceptCode":"C27080","definition":"Refractory anemia with excess blasts in transformation (RAEB-T) is characterised by dysplastic features of the myeloid and usually erythroid progenitor cells in the bone marrow and an increased number of myeloblasts in the peripheral blood.  The peripheral blood blast count ranges from 20% to 30%.  RAEB-T used to be a subcategory of myelodysplastic syndromes in the past.  Recently, the term has been eliminated from the WHO based classification of myelodysplastic syndromes.  The reason is that the percentage of peripheral blood blasts required for the diagnosis of acute myeloid leukemia has been reduced to 20%.  The elimination of the RAEB-T term by the WHO experts has created confusion and ongoing arguments.  Currently, according to WHO classification, the vast majority of RAEB-T cases are best classified as acute leukemias (acute leukemias with multilineage dysplasia following myelodysplastic syndrome).  A minority of cases are part of RAEB-2.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D88FEC4-0F1C-54AB-E050-BB89AD4366F5","latestVersionIndicator":"Yes","beginDate":"2015-08-17","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1D88FEC4-0F37-54AB-E050-BB89AD4366F5","beginDate":"2015-08-17","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-17","modifiedBy":"ONEDATA","dateModified":"2015-08-17","deletedIndicator":"No"},{"value":"MDS RAEB","valueDescription":"Myelodysplastic Syndrome Refractory Anemia with Excess Blasts","ValueMeaning":{"publicId":"4973756","version":"1","preferredName":"Myelodysplastic Syndrome Refractory Anemia with Excess Blasts","longName":"4973756","preferredDefinition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001): A myelodysplastic syndrome characterized by the presence of 5-19% myeloblasts in the bone marrow or 2-19% blasts in the peripheral blood. It includes two categories: RAEB-1and RAEB-2. Cases with significant bone marrow reticulin fibrosis are called RAEB with fibrosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome","conceptCode":"C3247","definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Myelodysplastic Syndrome with Excess Blasts","conceptCode":"C7506","definition":"Myelodysplastic syndrome characterized by the presence of 5-9% blasts in bone marrow and 2-9% blasts in peripheral blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D88FEC4-0F44-54AB-E050-BB89AD4366F5","latestVersionIndicator":"Yes","beginDate":"2015-08-17","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1D88FEC4-0F5F-54AB-E050-BB89AD4366F5","beginDate":"2015-08-17","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-17","modifiedBy":"ONEDATA","dateModified":"2015-08-17","deletedIndicator":"No"},{"value":"MDS RARS","valueDescription":"Myelodysplastic Syndrome Refractory Anemia with Ring Sideroblasts","ValueMeaning":{"publicId":"4973757","version":"1","preferredName":"Myelodysplastic Syndrome Refractory Anemia with Ring Sideroblasts","longName":"4973757","preferredDefinition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001): A myelodysplastic syndrome characterized by an anemia in which 15% or more of the erythroid precursors are ring sideroblasts.  The ring sideroblast is an erythroid precursor in which one third or more of the nucleus is encircled by granules which are positive for iron stain. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome","conceptCode":"C3247","definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Myelodysplastic Syndrome with Ring Sideroblasts","conceptCode":"C4036","definition":"A myelodysplastic syndrome characterized by an anemia in which 15% or more of the erythroid precursors are ring sideroblasts.  The ring sideroblast is an erythroid precursor in which one third or more of the nucleus is encircled by granules which are positive for iron stain. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D88FEC4-0F6C-54AB-E050-BB89AD4366F5","latestVersionIndicator":"Yes","beginDate":"2015-08-17","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1D88FEC4-0F87-54AB-E050-BB89AD4366F5","beginDate":"2015-08-17","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-17","modifiedBy":"ONEDATA","dateModified":"2015-08-17","deletedIndicator":"No"},{"value":"MDS RA","valueDescription":"Myelodysplastic Syndrome Refractory Anemia","ValueMeaning":{"publicId":"4973758","version":"1","preferredName":"Myelodysplastic Syndrome Refractory Anemia","longName":"4973758","preferredDefinition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001): A myelodysplastic syndrome characterized mainly by dysplasia of the erythroid series.  Refractory anemia is uncommon.  It is primarily a disease of older adults.  The median survival exceeds 5 years.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome","conceptCode":"C3247","definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Refractory Anemia","conceptCode":"C2872","definition":"A myelodysplastic syndrome characterized mainly by dysplasia of the erythroid series.  Refractory anemia is uncommon.  It is primarily a disease of older adults.  The median survival exceeds 5 years.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D88FEC4-0F94-54AB-E050-BB89AD4366F5","latestVersionIndicator":"Yes","beginDate":"2015-08-17","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1D88FEC4-0FAF-54AB-E050-BB89AD4366F5","beginDate":"2015-08-17","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-17","modifiedBy":"ONEDATA","dateModified":"2015-08-17","deletedIndicator":"No"},{"value":"AML not further subclassified","valueDescription":"AML not further subclassified","ValueMeaning":{"publicId":"4860799","version":"1","preferredName":"AML not further subclassified","longName":"4860799","preferredDefinition":"AML not further subclassified","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"18199818-F759-18F2-E050-BB89AD4304B5","latestVersionIndicator":"Yes","beginDate":"2015-06-09","endDate":null,"createdBy":"LEEW","dateCreated":"2015-06-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1D88FEC4-0FB9-54AB-E050-BB89AD4366F5","beginDate":"2015-08-17","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-17","modifiedBy":"ONEDATA","dateModified":"2015-08-17","deletedIndicator":"No"},{"value":"FAB M7","valueDescription":"Acute Megakaryoblastic Leukemia","ValueMeaning":{"publicId":"2836783","version":"1","preferredName":"Acute Megakaryoblastic Leukemia","longName":"2836783","preferredDefinition":"An acute myeloid leukemia in which at least 50% of the blasts are of megakaryocytic lineage.  The prognosis is usually poor.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Megakaryoblastic Leukemia","conceptCode":"C3170","definition":"An acute myeloid leukemia in which at least 50% of the blasts are of megakaryocytic lineage. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62459E81-67CE-8F6B-E040-BB89AD43368B","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1D88FEC4-0FCF-54AB-E050-BB89AD4366F5","beginDate":"2015-08-17","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-17","modifiedBy":"ONEDATA","dateModified":"2015-08-17","deletedIndicator":"No"},{"value":"FAB M6","valueDescription":"Acute Erythroid Leukemia","ValueMeaning":{"publicId":"2836778","version":"1","preferredName":"Acute Erythroid Leukemia","longName":"2836778","preferredDefinition":"An acute myeloid leukemia characterized by a predominant immature erythroid population.  There are two subtypes recognized: erythroleukemia and pure erythroid leukemia. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Erythroid Leukemia","conceptCode":"C8923","definition":"An acute myeloid leukemia characterized by a predominant immature erythroid population.  There are two subtypes recognized: erythroleukemia and pure erythroid leukemia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62459E81-675B-8F6B-E040-BB89AD43368B","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"HARTLEYG","dateModified":"2016-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1D88FEC4-0FE6-54AB-E050-BB89AD4366F5","beginDate":"2015-08-17","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-17","modifiedBy":"ONEDATA","dateModified":"2015-08-17","deletedIndicator":"No"},{"value":"FAB M5","valueDescription":"Acute monoblastic leukemia (FAB type M5)","ValueMeaning":{"publicId":"4973760","version":"1","preferredName":"Acute monoblastic leukemia (FAB type M5)","longName":"4973760v1.00","preferredDefinition":"Acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage, including monoblasts, promonocytes, and monocytes. Bleeding disorders are common presenting features.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Monoblastic and Monocytic Leukemia","conceptCode":"C7318","definition":"Acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage, including monoblasts, promonocytes, and monocytes. Bleeding disorders are common presenting features.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D88FEC4-0FF3-54AB-E050-BB89AD4366F5","latestVersionIndicator":"Yes","beginDate":"2015-08-17","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-17","modifiedBy":"KUMMEROA","dateModified":"2023-08-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1D88FEC4-100E-54AB-E050-BB89AD4366F5","beginDate":"2015-08-17","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-17","modifiedBy":"ONEDATA","dateModified":"2015-08-17","deletedIndicator":"No"},{"value":"FAB M4","valueDescription":"Acute myelomonocytic leukemia, FAB M4, in remission","ValueMeaning":{"publicId":"4973762","version":"1","preferredName":"Acute myelomonocytic leukemia, FAB M4, in remission","longName":"4973762","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute myelomonocytic leukemia, FAB M4, in remission","conceptCode":"C1960890","definition":"No Value Exists","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D88FEC4-101B-54AB-E050-BB89AD4366F5","latestVersionIndicator":"Yes","beginDate":"2015-08-17","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1D88FEC4-1036-54AB-E050-BB89AD4366F5","beginDate":"2015-08-17","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-17","modifiedBy":"ONEDATA","dateModified":"2015-08-17","deletedIndicator":"No"},{"value":"FAB M3","valueDescription":"Acute Promyelocytic Leukemia with t(15;17)(q22;q12); PML-RARA","ValueMeaning":{"publicId":"4722782","version":"1","preferredName":"Acute Promyelocytic Leukemia with t(15;17)(q22;q12); PML-RARA","longName":"4722782","preferredDefinition":"An acute myeloid leukemia (AML) in which abnormal promyelocytes predominate.  It is characterized by the t(15;17)(q22;q12) translocation.  There are two variants: the typical and microgranular variant.  This AML is particularly sensitive to treatment with all trans-retinoic acid and has a favorable prognosis.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML-RARA","conceptCode":"C3182","definition":"An acute myeloid leukemia (AML) in which abnormal promyelocytes predominate. It is characterized by the PML-RARA fusion. There are two variants: the typical and microgranular variant.  This AML is particularly sensitive to treatment with all trans-retinoic acid and has a favorable prognosis. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F8A7B21-22C4-7895-E050-BB89AD43579D","latestVersionIndicator":"Yes","beginDate":"2015-02-20","endDate":null,"createdBy":"LUY","dateCreated":"2015-02-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1D88FEC4-104B-54AB-E050-BB89AD4366F5","beginDate":"2015-08-17","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-17","modifiedBy":"ONEDATA","dateModified":"2015-08-17","deletedIndicator":"No"},{"value":"FAB M2","valueDescription":"Acute Myeloid Leukemia with Maturation","ValueMeaning":{"publicId":"2836809","version":"1","preferredName":"Acute Myeloid Leukemia with Maturation","longName":"2836809","preferredDefinition":"An acute myeloid leukemia (AML) characterized by blasts with evidence of maturation to more mature neutrophils. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with Maturation","conceptCode":"C3250","definition":"An acute myeloid leukemia (AML) characterized by blasts with evidence of maturation to more mature neutrophils. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6246BA48-A992-2000-E040-BB89AD437D62","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"HARTLEYG","dateModified":"2016-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1D88FEC4-1061-54AB-E050-BB89AD4366F5","beginDate":"2015-08-17","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-17","modifiedBy":"ONEDATA","dateModified":"2015-08-17","deletedIndicator":"No"},{"value":"FAB M1","valueDescription":"French-American-British Classification M1 Stage Finding","ValueMeaning":{"publicId":"4973763","version":"1","preferredName":"French-American-British Classification M1 Stage Finding","longName":"4973763","preferredDefinition":"A classification system for acute myeloid leukemias, acute lymphoblastic leukemias, and myelodysplastic syndromes.  It is based on the morphologic and cytochemical evaluation of bone marrow and peripheral blood smears.: A clinical and/or pathologic distant metastasis TNM finding indicating the spread of cancer to distant anatomic sites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"French-American-British Classification","conceptCode":"C91220","definition":"A classification system for acute myeloid leukemias, acute lymphoblastic leukemias, and myelodysplastic syndromes.  It is based on the morphologic and cytochemical evaluation of bone marrow and peripheral blood smears.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"M1 TNM Finding","conceptCode":"C48700","definition":"A clinical and/or pathologic distant metastasis TNM finding indicating the spread of cancer to distant anatomic sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D88FEC4-106E-54AB-E050-BB89AD4366F5","latestVersionIndicator":"Yes","beginDate":"2015-08-17","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1D88FEC4-1089-54AB-E050-BB89AD4366F5","beginDate":"2015-08-17","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-17","modifiedBy":"ONEDATA","dateModified":"2015-08-17","deletedIndicator":"No"},{"value":"FAB M0","valueDescription":"French-American-British Classification M0 Stage Finding","ValueMeaning":{"publicId":"4973764","version":"1","preferredName":"French-American-British Classification M0 Stage Finding","longName":"4973764","preferredDefinition":"A classification system for acute myeloid leukemias, acute lymphoblastic leukemias, and myelodysplastic syndromes.  It is based on the morphologic and cytochemical evaluation of bone marrow and peripheral blood smears.: A distant metastasis TNM finding indicating that there is no evidence of distant metastasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"French-American-British Classification","conceptCode":"C91220","definition":"A classification system for acute myeloid leukemias, acute lymphoblastic leukemias, and myelodysplastic syndromes.  It is based on the morphologic and cytochemical evaluation of bone marrow and peripheral blood smears.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"M0 TNM Finding","conceptCode":"C48699","definition":"A distant metastasis TNM finding indicating that there is no evidence of distant metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D88FEC4-1096-54AB-E050-BB89AD4366F5","latestVersionIndicator":"Yes","beginDate":"2015-08-17","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1D88FEC4-10B1-54AB-E050-BB89AD4366F5","beginDate":"2015-08-17","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-17","modifiedBy":"ONEDATA","dateModified":"2015-08-17","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"4973751","version":"1","preferredName":"Leukemia Primary Morphology Type","preferredDefinition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.:Occurring first in time or sequence; original; of greatest rank or importance or value.:The science of the form and structure of organisms (plants, animals, and other forms of life), or of their parts, and the study or science of the same.  In pathology, the specific appearance of cells and tissues (normal and abnormal) under the light or electron microscope.:Something distinguishable as an identifiable class based on common qualities.","longName":"C3161:C25251:C17943:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leukemia","conceptCode":"C3161","definition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Primary","conceptCode":"C25251","definition":"Occurring first in time or sequence; original; of greatest rank or importance or value.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Morphology","conceptCode":"C17943","definition":"The science of the form and structure of organisms (plants, animals, and other forms of life), or of their parts, and the study or science of the same.  In pathology, the specific appearance of cells and tissues (normal and abnormal) under the light or electron microscope.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D88FEC4-0E80-54AB-E050-BB89AD4366F5","latestVersionIndicator":"Yes","beginDate":"2015-08-17","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-17","modifiedBy":"ONEDATA","dateModified":"2015-08-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D88FEC4-0E91-54AB-E050-BB89AD4366F5","latestVersionIndicator":"Yes","beginDate":"2015-08-17","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-17","modifiedBy":"WONGW","dateModified":"2015-08-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"3303197","version":"1","longName":"Phase 1/Pilot Consortium","context":"COG"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Primary morphology","type":"Preferred Question Text","description":"Primary morphology","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D88FEC4-10DB-54AB-E050-BB89AD4366F5","latestVersionIndicator":"Yes","beginDate":"2015-08-17","endDate":null,"createdBy":"WONGW","dateCreated":"2015-08-17","modifiedBy":"WONGW","dateModified":"2015-08-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}